• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有保护性的低亲和力抗肿瘤CD8 + T细胞被调节性T细胞选择性地削弱。

Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.

作者信息

Sugiyarto Gessa, Prossor David, Dadas Osman, Arcia-Anaya E David, Elliott Tim, James Edward

机构信息

Centre for Cancer Immunology, School of Cancer Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton, UK.

Institute for Life sciences, University of Southampton, Southampton, UK.

出版信息

Immunother Adv. 2020 Nov 25;1(1):ltaa001. doi: 10.1093/immadv/ltaa001. eCollection 2021 Jan.

DOI:10.1093/immadv/ltaa001
PMID:33748824
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7958313/
Abstract

OBJECTIVES

Regulatory T cells (Treg) play a major role in the suppression of protective anti-tumour T cell responses. In the CT26 BALB/c murine model of colorectal carcinoma, Tregs differentially suppress responses to two characterised CD8+ T epitopes, AH1 and GSW11, which results in an absence of detectable IFN-γ-producing GSW11-specific T cells in the spleen and lymph nodes of tumour challenged mice. Activation of GSW11-specific T cells correlates with protection against tumour progression. We wanted to examine the presence of non-functional GSW11-specific T cells in Treg replete and depleted mice, assess their phenotype and their affinity compared to AH1-specific T cells.

METHODS

We used peptide-specific tetramers to identify tumour-specific CD8+ T cells and assessed the cell surface expression of markers associated with exhaustion (PD-1, Tim3 and Lag-3) and their function by IFN-g production using flow cytometry. We also assessed the T cell receptor (TcR) clonality of tumour-specific T cells. Tetramer competition assays were performed to determine the relative affinity of identified TcR.

RESULTS

Here, we show that GSW11-specific T cells are in fact induced in Treg-replete, CT26-bearing mice, where they make up the majority of tumour-infiltrating CD8+ lymphocytes, but exhibit an 'exhausted' phenotype. This dysfunctional phenotype is induced early in the anti-tumour response in tumours. Depletion of Tregs prior to tumour challenge correlates with an altered T cell receptor (TcR) repertoire. Moreover, the avidity of GSW11-specific TcRs that expanded in the absence of Tregs was significantly lower compared with TcRs of CD8+populations that were diminished in protective anti-tumour responses.

CONCLUSION

Our results indicate that Tregs suppress the induction of protective anti-tumour T cell responses and may signify that low-avidity T cells play an important role in this protection.

摘要

目的

调节性T细胞(Treg)在抑制保护性抗肿瘤T细胞反应中起主要作用。在CT26 BALB/c小鼠结直肠癌模型中,Tregs对两种已鉴定的CD8 + T细胞表位AH1和GSW11的反应有差异地抑制,这导致在肿瘤攻击小鼠的脾脏和淋巴结中缺乏可检测到的产生IFN-γ的GSW11特异性T细胞。GSW11特异性T细胞的激活与抗肿瘤进展的保护相关。我们想检查在Treg充足和缺失的小鼠中是否存在无功能的GSW11特异性T细胞,评估它们的表型以及与AH1特异性T细胞相比的亲和力。

方法

我们使用肽特异性四聚体来鉴定肿瘤特异性CD8 + T细胞,并通过流式细胞术评估与耗竭相关的标志物(PD-1、Tim3和Lag-3)的细胞表面表达及其通过IFN-γ产生的功能。我们还评估了肿瘤特异性T细胞的T细胞受体(TcR)克隆性。进行四聚体竞争试验以确定鉴定的TcR的相对亲和力。

结果

在这里,我们表明在Treg充足的荷CT26小鼠中实际上诱导了GSW11特异性T细胞,它们构成了肿瘤浸润CD8 +淋巴细胞的大多数,但表现出“耗竭”表型。这种功能失调的表型在肿瘤的抗肿瘤反应早期就被诱导。在肿瘤攻击前耗尽Tregs与T细胞受体(TcR)库的改变相关。此外,与在保护性抗肿瘤反应中减少的CD8 +群体的TcR相比,在没有Tregs的情况下扩增的GSW11特异性TcR的亲和力明显更低。

结论

我们的结果表明,Tregs抑制保护性抗肿瘤T细胞反应的诱导,这可能意味着低亲和力T细胞在这种保护中起重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/e1881354be62/ltaa001_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/6374d8a0b0a4/ltaa001_iffig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/9fadbba717de/ltaa001_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/0e7e5c30a449/ltaa001_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/e431233d8fcd/ltaa001_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/8a14172b75be/ltaa001_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/e1881354be62/ltaa001_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/6374d8a0b0a4/ltaa001_iffig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/9fadbba717de/ltaa001_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/0e7e5c30a449/ltaa001_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/e431233d8fcd/ltaa001_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/8a14172b75be/ltaa001_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3770/9585684/e1881354be62/ltaa001_fig5.jpg

相似文献

1
Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.具有保护性的低亲和力抗肿瘤CD8 + T细胞被调节性T细胞选择性地削弱。
Immunother Adv. 2020 Nov 25;1(1):ltaa001. doi: 10.1093/immadv/ltaa001. eCollection 2021 Jan.
2
Reactivation of low avidity tumor-specific CD8 T cells associates with immunotherapeutic efficacy of anti-PD-1.低亲和度肿瘤特异性 CD8 T 细胞的再激活与抗 PD-1 的免疫治疗疗效相关。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007114.
3
Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.肿瘤相关调节性 T 细胞(Tregs)通过促进 T 细胞功能障碍和限制肿瘤浸润 CD8+T 细胞的克隆多样性来阻碍抗肿瘤免疫。
J Immunother Cancer. 2022 May;10(5). doi: 10.1136/jitc-2022-004605.
4
Anti-PD-1 inhibits Foxp3 Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model.抗程序性死亡蛋白1(Anti-PD-1)抑制叉头框蛋白3(Foxp3)调节性T细胞(Treg细胞)的转化,并释放肿瘤内效应T细胞,从而增强癌症疫苗在小鼠模型中的疗效。
Cancer Immunol Immunother. 2016 Dec;65(12):1491-1498. doi: 10.1007/s00262-016-1906-6. Epub 2016 Sep 28.
5
Immunotherapy of CT26 murine tumors is characterized by an oligoclonal response of tissue-resident memory T cells against the AH1 rejection antigen.CT26 鼠肿瘤的免疫治疗表现为组织驻留记忆 T 细胞针对 AH1 排斥抗原的寡克隆反应。
Eur J Immunol. 2020 Oct;50(10):1591-1597. doi: 10.1002/eji.201948433. Epub 2020 Jun 9.
6
Therapeutic depletion of CCR8 tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy.CCR8 肿瘤浸润调节性 T 细胞的治疗性耗竭引发抗肿瘤免疫,并与抗 PD-1 治疗协同作用。
J Immunother Cancer. 2021 Feb;9(2). doi: 10.1136/jitc-2020-001749.
7
TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer.TIM3-FOXP3调节性T细胞是癌症中T细胞功能障碍的组织特异性促进因子。
Oncoimmunology. 2013 Apr 1;2(4):e23849. doi: 10.4161/onci.23849.
8
Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy.调控对鼠 5T4 肿瘤相关抗原的自身免疫:对免疫治疗的启示。
Cancer Immunol Immunother. 2012 Jul;61(7):1005-18. doi: 10.1007/s00262-011-1167-3. Epub 2011 Nov 30.
9
Targeting tumor-infiltrating CCR8 regulatory T cells induces antitumor immunity through functional restoration of CD4 T and CD8 T cells in colorectal cancer.靶向肿瘤浸润性 CCR8 调节性 T 细胞通过恢复结直肠癌中 CD4 T 和 CD8 T 细胞的功能诱导抗肿瘤免疫。
J Transl Med. 2024 Jul 30;22(1):709. doi: 10.1186/s12967-024-05518-8.
10
PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.PD-L1 检查点抑制缩小了慢性淋巴细胞脉络丛脑膜炎病毒感染中抗原特异性 T 细胞受体库。
J Virol. 2020 Aug 31;94(18). doi: 10.1128/JVI.00795-20.

引用本文的文献

1
CD45 sequestration lowers the signaling threshold in lymphocytes and enhances anti-tumor immunity.CD45隔离降低淋巴细胞中的信号阈值并增强抗肿瘤免疫力。
bioRxiv. 2025 Aug 1:2025.07.29.667400. doi: 10.1101/2025.07.29.667400.
2
The Current Status of T Cell Receptor (TCR) Repertoire Analysis in Colorectal Cancer.T细胞受体(TCR)库分析在结直肠癌中的现状
Int J Mol Sci. 2025 Mar 17;26(6):2698. doi: 10.3390/ijms26062698.
3
Low-avidity T cells drive endogenous tumor immunity in mice and humans.低亲和力T细胞驱动小鼠和人类的内源性肿瘤免疫。

本文引用的文献

1
Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.具有干性特征的肿瘤内 Tcf1PD-1CD8 T 细胞促进接种疫苗和检查点阻断免疫治疗后的肿瘤控制。
Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8.
2
In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors.体内光标记肿瘤浸润细胞揭示了 T 细胞亚群从肿瘤中高度受调控的流出。
Proc Natl Acad Sci U S A. 2017 May 30;114(22):5677-5682. doi: 10.1073/pnas.1618446114. Epub 2017 May 15.
3
Nat Immunol. 2025 Feb;26(2):240-251. doi: 10.1038/s41590-024-02044-z. Epub 2025 Jan 9.
4
Cancer neoepitopes viewed through negative selection and peripheral tolerance: a new path to cancer vaccines.通过负选择和外周耐受观察到的癌症新抗原:癌症疫苗的新途径。
J Clin Invest. 2024 Mar 1;134(5):e176740. doi: 10.1172/JCI176740.
5
DGKα/ζ inhibition lowers the TCR affinity threshold and potentiates antitumor immunity.DGKα/ζ 抑制降低 TCR 亲和力阈值并增强抗肿瘤免疫。
Sci Adv. 2023 Nov 24;9(47):eadk1853. doi: 10.1126/sciadv.adk1853.
6
Reactivation of low avidity tumor-specific CD8 T cells associates with immunotherapeutic efficacy of anti-PD-1.低亲和度肿瘤特异性 CD8 T 细胞的再激活与抗 PD-1 的免疫治疗疗效相关。
J Immunother Cancer. 2023 Aug;11(8). doi: 10.1136/jitc-2023-007114.
7
Transforming Growth Factor-β Blockade in Pancreatic Cancer Enhances Sensitivity to Combination Chemotherapy.转化生长因子-β 阻断在胰腺癌中的应用增强了联合化疗的敏感性。
Gastroenterology. 2023 Oct;165(4):874-890.e10. doi: 10.1053/j.gastro.2023.05.038. Epub 2023 May 30.
8
Introducing .介绍。
Immunother Adv. 2020 Nov 25;1(1):ltaa009. doi: 10.1093/immadv/ltaa009. eCollection 2021 Jan.
Second- and third-generation drugs for immuno-oncology treatment-The more the better?
免疫肿瘤治疗的第二代和第三代药物——越多越好?
Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10.
4
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.人类组织淋巴细胞的转录图谱揭示了肿瘤浸润性调节性T细胞的独特性。
Immunity. 2016 Nov 15;45(5):1135-1147. doi: 10.1016/j.immuni.2016.10.021.
5
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer.调节性T细胞在人类乳腺癌中表现出不同特征。
Immunity. 2016 Nov 15;45(5):1122-1134. doi: 10.1016/j.immuni.2016.10.032.
6
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.免疫原性抗原的密度并不能解释黑色素瘤中T细胞炎症性肿瘤微环境的存在与否。
Proc Natl Acad Sci U S A. 2016 Nov 29;113(48):E7759-E7768. doi: 10.1073/pnas.1609376113. Epub 2016 Nov 11.
7
T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections.T 细胞因子 1 表达的记忆样 CD8(+)T 细胞维持对慢性病毒感染的免疫应答。
Immunity. 2016 Aug 16;45(2):415-27. doi: 10.1016/j.immuni.2016.07.021.
8
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.肿瘤特异性T细胞功能障碍是一种在肿瘤发生早期启动的动态抗原驱动的分化程序。
Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9.
9
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.定义在PD-1治疗后提供增殖爆发的CD8+ T细胞。
Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.
10
Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis.肿瘤浸润性FoxP3 +调节性T细胞在癌症中的预后价值:一项系统评价和荟萃分析
Sci Rep. 2015 Oct 14;5:15179. doi: 10.1038/srep15179.